PMID- 38150142
OWN - NLM
STAT- MEDLINE
DCOM- 20240305
LR  - 20240305
IS  - 2366-0058 (Electronic)
VI  - 49
IP  - 3
DP  - 2024 Mar
TI  - Percutaneous cryoablation of 100 anterior renal tumors: safety and technical 
      success.
PG  - 919-926
LID - 10.1007/s00261-023-04134-2 [doi]
AB  - PURPOSE: To assess the safety, technical success, and clinical outcomes of 
      percutaneous cryoablation (PCA) in patients with anterior renal tumors. METHODS: 
      A retrospective analysis of patients with anterior renal tumors, defined as 
      tumors at or anterior to the level of the renal pelvis, treated with CT-guided 
      PCA from 2008 to 2022. Summary statistics included demographics and baseline 
      tumor attributes. Treatment and follow-up metrics included primary and secondary 
      technical success, adverse events (AEs) according to the SIR classification, 
      local recurrence, overall survival (OS), and cancer-specific survival (CSS)). 100 
      patients (60 males; mean age: 63, mean BMI: 33, mean Charlson comorbidity 
      index:6) with 100 anterior renal tumors were included. RESULTS: 78% of tumors 
      were T1a and 22% T1b with mean maximal tumoral dimension of 29 mm (range: 
      6-62 mm) and mean distance to nearest critical structure 9 mm (range: 0-40 mm). 
      Mean follow-up was 20.9 months (range: 3-103). 28% of PCAs required 
      hydrodissection. Technical success was achieved in 92% of patients; with six 
      remaining patients undergoing successful repeat PCA (secondary technical success: 
      98%). The remaining two patients without primary technical success were either 
      surveilled or had a benign pathology on resulted concomitant biopsy. Four 
      patients (4%) had major AEs (hemorrhage requiring prolonged admission, 
      transfusion, or embolization (n = 3), perinephric abscess requiring drainage 
      (n = 1)) and 27% had minor AEs. Eight patients (8%) had recurrence with a 
      one-year OS of 94% and CSS of 100%. All recurrences underwent repeat ablation 
      without additional recurrence and 3/8 (38%) were T1b and 5/8 (63%) were T1a 
      tumors. CONCLUSION: PCA of anterior renal tumors can be performed safely with 
      high rates of technical and oncologic success.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Raja, Junaid
AU  - Raja J
AD  - Division of Vascular and Interventional Radiology, Department of Radiology, 
      University of Alabama at Birmingham, 619 19th St SNHB 623, Birmingham, AL, 35249, 
      USA.
FAU - Pigg, Richard
AU  - Pigg R
AD  - Division of Vascular and Interventional Radiology, Department of Radiology, 
      University of Alabama at Birmingham, 619 19th St SNHB 623, Birmingham, AL, 35249, 
      USA.
FAU - Li, Yufeng
AU  - Li Y
AD  - Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
FAU - Savage, Cody
AU  - Savage C
AD  - Division of Vascular and Interventional Radiology, Department of Radiology, 
      University of Alabama at Birmingham, 619 19th St SNHB 623, Birmingham, AL, 35249, 
      USA.
FAU - Caridi, Theresa M
AU  - Caridi TM
AD  - Division of Vascular and Interventional Radiology, Department of Radiology, 
      University of Alabama at Birmingham, 619 19th St SNHB 623, Birmingham, AL, 35249, 
      USA.
FAU - Huang, Junjian
AU  - Huang J
AD  - Division of Vascular and Interventional Radiology, Department of Radiology, 
      University of Alabama at Birmingham, 619 19th St SNHB 623, Birmingham, AL, 35249, 
      USA.
FAU - Gunn, Andrew J
AU  - Gunn AJ
AUID- ORCID: 0000-0001-9081-446X
AD  - Division of Vascular and Interventional Radiology, Department of Radiology, 
      University of Alabama at Birmingham, 619 19th St SNHB 623, Birmingham, AL, 35249, 
      USA. agunn@uabmc.edu.
LA  - eng
PT  - Journal Article
DEP - 20231227
PL  - United States
TA  - Abdom Radiol (NY)
JT  - Abdominal radiology (New York)
JID - 101674571
SB  - IM
MH  - Male
MH  - Humans
MH  - Middle Aged
MH  - *Carcinoma, Renal Cell/diagnostic imaging/surgery
MH  - *Cryosurgery/methods
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Tomography, X-Ray Computed
MH  - *Kidney Neoplasms/diagnostic imaging/surgery
OTO - NOTNLM
OT  - Ablation
OT  - Anterior
OT  - Renal cell carcinoma
OT  - Safety
EDAT- 2023/12/27 12:42
MHDA- 2024/03/05 06:47
CRDT- 2023/12/27 11:11
PHST- 2023/06/28 00:00 [received]
PHST- 2023/11/22 00:00 [accepted]
PHST- 2023/11/16 00:00 [revised]
PHST- 2024/03/05 06:47 [medline]
PHST- 2023/12/27 12:42 [pubmed]
PHST- 2023/12/27 11:11 [entrez]
AID - 10.1007/s00261-023-04134-2 [pii]
AID - 10.1007/s00261-023-04134-2 [doi]
PST - ppublish
SO  - Abdom Radiol (NY). 2024 Mar;49(3):919-926. doi: 10.1007/s00261-023-04134-2. Epub 
      2023 Dec 27.